

I. In the Claims (Clean Sheet)

5. A vaccine comprising an avian reovirus belonging to an antigenic class of avian reoviruses, wherein the avian reovirus is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 75% in a plaque reduction assay and a pharmaceutical acceptable carrier or diluent.

6. The vaccine according to claim 5, which is in a live attenuated form.

7. The vaccine according to claim 5, which is in an inactivated form.

8. The vaccine according to claim 5, which further comprises an adjuvant.

9. The vaccine according to claim 5, which further comprises one or more vaccine components of other pathogens infectious to poultry.

14. A vaccine comprising an avian reovirus which is avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, and a pharmaceutically acceptable carrier or diluent.

16. The vaccine of Claim 9 wherein the one or more vaccine components comprises at least one vaccine component selected from the group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, fowl adenovirus, EDS virus and turkey rhinotracheitis virus.

17. The vaccine of Claim 9 wherein the one or more vaccine components are either one of a live attenuated form or an inactivated form.

18. A vaccine comprising an avian reovirus which positively reacts with polyclonal avian reovirus antiserum but not with monoclonal antibodies identified by accessions nos.

99011472, 99011473 and 99011474, samples of which are deposited at the ECACC, and causes a reduction of plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475.

19. The vaccine of Claim 18 further comprising at least one more vaccine component.
20. The vaccine according to claim 18, which is in a live attenuated form.
21. The vaccine according to claim 18, which is in an inactivated form.
22. The vaccine according to claim 18, which further comprises an adjuvant.
23. The vaccine of Claim 18 wherein the reovirus causes a reduction of plaques formed by avian reovirus ERS of at least 75% in a plaque reduction assay.
24. The vaccine of Claim 5 wherein the avian reovirus is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 80% in a plaque reduction assay.
25. The vaccine of Claim 5 wherein the avian reovirus is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 90% in a plaque reduction assay.

18. II. In the Claims (Marked Version)

Please add the following Claims: _____

16. The vaccine of Claim 9 wherein the one or more vaccine components comprises at least one vaccine component selected from the group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, fowl adenovirus, EDS virus and turkey rhinotracheitis virus.
17. The vaccine of Claim 9 wherein the one or more vaccine components are either one of a live attenuated form or an inactivated form.
18. A vaccine comprising an avian reovirus which positively reacts with polyclonal avian reovirus antiserum but not with monoclonal antibodies identified by accessions nos. 99011472, 99011473 and 99011474, samples of which are deposited at the ECACC, and is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475.
19. The vaccine of Claim 18 further comprising at least one more vaccine component.
20. The vaccine according to claim 18, which is in a live attenuated form.
21. The vaccine according to claim 18, which is in an inactivated form.
22. The vaccine according to claim 18, which further comprises an adjuvant.
23. The vaccine of Claim 18 wherein the reovirus causes a reduction of plaques formed by avian reovirus ERS of at least 75% in a plaque reduction assay.
24. The vaccine of Claim 5 wherein the avian reovirus is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus